In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol

Journal of Controlled Release

Volumn 130, Issue 1, 2008, Pages 29-37

  Jinno, Jun ichi ^a   Kamada, Naoki ^a   Miyake, Masateru ^a   Yamada, Keigo ^a   Mukai, Tadashi ^a   Odomi, Masaaki ^a   Toguchi, Hajime ^a   Liversidge, Gary G ^c   Higaki, Kazutaka ^b   Kimura, Toshikiro ^b  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c Elan Drug Delivery Inc   (United States)

Author keywords

Bioavailability; Cilostazol; Dissolution; Flow through cell; Wet milling

Indexed keywords

ANIONIC SURFACTANTS; BIOCHEMISTRY; CANNING; CHEMOTHERAPY; CONCENTRATION (PROCESS); CORRELATION METHODS; CRYSTALLOGRAPHY; DEWATERING; DISSOLUTION; DRUG DELIVERY; DRUG DOSAGE; DYES; FOOD PRESERVATION; SODIUM; SODIUM SULFATE; SUGAR (SUCROSE); SUGARS; SULFATE MINERALS; SURFACE ACTIVE AGENTS; THEOREM PROVING;

BIOAVAILABILITY ENHANCEMENT; CARRIER (CO); CELL METHOD (CM); CILOSTAZOL; CLOSED-LOOP SYSTEMS; CO PRECIPITATES; CONCENTRATION (COMPOSITION); CRITICAL MICELLAR CONCENTRATION (CMC); FLOW THROUGH; HYDROPHILIC POLYMERS; IN VITRO DISSOLUTION; IN-VITRO; IN-VIVO; MEDIAN DIAMETERS; ORAL BIOAVAILABILITY; SODIUM LAURYL SULFATE (SLS); SPRAY-DRYING METHOD; SUB MICRONS;

WATER FILTRATION;

CILOSTAZOL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; MALE; PARTICLE SIZE; SOLUBILITY; TABLETS; TETRAZOLES;

EID: 48749094715     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.05.013     Document Type: Article

References (39)

1. Lipinski C. Poorly aqueous solubility: an industry wide problem in drug discovery. Am. Pharm. Rev. 5 (2002) 82-85
2. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
3. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44 (2000) 235-249
4. Fahr A., and Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin. Drug Deliv. 4 (2007) 403-416
5. Serajuddin A.T.M. Solid dispersions of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88 (1999) 1058-1066
6. Kondo N., Iwao T., Masuda H., Yamanouchi K., Ishihara Y., Yamada N., Haga T., Ogawa Y., and Yokoyama K. Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region. Chem. Pharm. Bull. (Tokyo) 41 (1993) 737-740
7. Liversidge G.G., and Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125 (1995) 91-97
8. Merisko-Liversidge E., Liversidge G.G., and Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18 (2003) 113-120
9. Wu Y., Loper A., Landis E., Hettrick L., Novak L., Lynn K., Chen C., Thompson K., Higgins R., Batra U., Shelukar S., Kwei G., and Storey D. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285 (2004) 135-146
10. Sauron R., Wilkins M., Jessent V., Dubois A., Maillot C., and Weil A. Absence of food effect with a 145 mg nanoparticle fenofibrate tablet formulation. Int. J. Clin. Pharm. Ther. 44 (2006) 64-70
11. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., and Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 111 (2006) 56-64
12. Hu J., Johnston K.P., and Williams III R.O. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev. Ind. Pharm. 30 (2004) 233-245
13. Keck C.M., and Muller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 62 (2006) 3-16
14. Muller R.H., Mader K., and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50 (2000) 161-177
15. Pouton C.W. Formulation of self-emulsifying drug delivery systems. Adv. Drug Deliv. Rev. 25 (1997) 47-58
16. Gursoy R.N., and Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 58 (2004) 173-182
17. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
18. Dai W., Dong L.C., and Song Y. Nanosizing of a drug/carrageenan complex to increase solubility and dissolution rate. Int. J. Pharm. 342 (2007) 201-207
19. Crisp M.T., Tucker C.J., Rogers T.L., Williams III R.O., and Johnston K.P. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. J. Control. Release 117 (2007) 351-359
20. Shimizu T., Osumi T., Niimi K., and Nakagawa K. Physico-chemical properties and stability of cilostazol. Arzneimittelforschung 35 (1985) 1117-1123
21. Toyobuku H., Tamai I., Ueno K., and Tsuji A. Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug. J. Pharm. Sci. 92 (2003) 2249-2259
22. Hints R.J., and Johnson K.C. The effect of particle size distribution on dissolution rate and oral absorption. Int. J. Pharm. 51 (1989) 9-17
23. Johnson K.C. Dissolution and absorption modeling: model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption. Drug Dev. Ind. Pharm. 29 (2003) 833-842
24. Bramer S.L., and Forbes W.P. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin. Pharmacokinet. 37 Suppl 2 (1999) 13-23
25. Hecq J., Deleers M., Fanara D., Vranckx H., and Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 299 (2005) 167-177
26. Dressman J.B., Amidon G.L., Reppas C., and Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15 (1998) 11-22
27. Cilostazol tablets. The Japanese Pharmacopoeia. 15th ed. (2006)
28. Kimura T., and Higaki K. Gastrointestinal transit and drug absorption. Biol. Pharm. Bull. 25 (2002) 149-164
29. Fujioka Y., Kadono K., Fujie Y., Metsugi Y., Ogawara K., Higaki K., and Kimura T. Prediction of oral absorption of griseofulvin, BCS class II drug, based on GITA model: utilization of a more suitable medium for in vitro dissolution study. J. Control. Release 119 (2007) 222-228
30. Fujioka Y., Metsugi Y., Ogawara K., Higaki K., and Kimura T. Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug. Int. J. Pharm. 352 (2008) 36-43
31. In: Wade A., and Weller P.J. (Eds). Handbook of Pharmaceutical Excipients. 2nd Ed. (1994), The Pharmaceutical Press, London 448-450
32. Sjokvist E., Nystrom C., and Alden M. Physicochemical aspects of drug release. XIII. The effect of sodium dodecyl sulfate additions on the structure and dissolution of a drug in solid dispersions. Int. J. Pharm. 69 (1991) 53-62
33. Bakatselou V., Oppenheim R.C., and Dressman J.B. Solubilization and wetting effects of bile salts on the dissolution of steroids. Pharm. Res. 8 (1991) 1461-1469
34. Tang L., Khan S.U., and Muhammad N.A. Evaluation and selection of bio-relevant dissolution media for a poorly water-soluble new chemical entity. Pharm. Dev. Technol. 6 (2001) 531-540
35. Sjokvist E., Nystrom C., Alden M., and Caram-Lelham N. Physicochemical aspects of drug release. XIV. The effects of some ionic and non-ionic surfactants on properties of a sparingly soluble drug in solid dispersions. Int. J. Pharm. 79 (1992) 123-133
36. Fell J.T., and Mohammad H.A.H. The wetting of powders by bile salt solutions and gastric juice. Int. J. Pharm. 125 (1995) 327-330
37. Kalantzi L., Goumas K., Kalioras V., Abrahamsson B., Dressman J.B., and Reppas C. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm. Res. 23 (2006) 165-176
38. Kalantzi L., Persson E., Polentarutti B., Abrahamsson B., Goumas K., Dressman J.B., and Reppas C. Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm. Res. 23 (2006) 1373-1381
39. Sunesen V.H., Pedersen B.L., Kristensen H.G., and Mullertz A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur. J. Pharm. Sci. 24 (2005) 305-313